NCNA
NuCana plcPrice
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
- R Mar 19 NuCana reported financial results for Q4 and full-year 2025, showing…
- R May 14 NuCana reported Q1 2026 results with a net loss of £3.9M, wider than…
- X Sep 15 Short interest falls 32.5% to 107.1K
- X Oct 15 Short interest jumps 45.1% to 145.0K
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.
- InstitutionsMIXED
Q2 2026: 2 added (0 new), 0 trimmed or exited.
- Short sellersBUILDING
Short interest +45.1% to 145.0K shares. 1.0 days to cover, ≈3.5% of shares.
- TrendDOWNTREND
13% below its 50-day average. New closing low $0.9600 on Oct 22.
Who's buying
13F· Q2 2026| Fund | Move | Value |
|---|---|---|
| CITADEL ADVISORS LLC | ADD | $41.2K |
| RHUMBLINE ADVISERS | ADD | $7.1K |
| MORGAN STANLEY | NEAR_EXIT | $3.00 |
| RHUMBLINE ADVISERS | DOUBLED | $17.7K |
| UBS Group AG | TRIM | $13.2K |
| MORGAN STANLEY | DOUBLED | $378.00 |
| RHUMBLINE ADVISERS | DOUBLED | $459.00 |
| RHUMBLINE ADVISERS | ADD | $1.6K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
last action Aug 2024| Date | Firm | Rating |
|---|---|---|
| Aug 19, 2024 | Oppenheimer REITERATE | Outperform |
| Jul 23, 2024 | Oppenheimer REITERATE | Outperform |
| Jul 22, 2024 | Oppenheimer MAINTAIN | Outperform |
| Apr 1, 2024 | Oppenheimer REITERATE | Outperform |
| Nov 21, 2023 | Oppenheimer REITERATE | Outperform |
| Sep 6, 2023 | Truist Securities REITERATE | Buy |
Insider ledger
Form 4| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 19, 2026 | Levy Elliott M. Director | TO ISSUER | 23,811,896 sh |
| Jun 19, 2026 | Bloss Jeffrey D. Chief Medical Officer | TO ISSUER | 36,539,720 sh |
| Apr 15, 2026 | Bruce Theresa Margaret Ms Chief Operating Officer | AWARD | 132,600,130 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $0.00 |
| Next Q | — | — | — | $0.00 |
| Current FY | — | — | — | $0.00 |
| Next FY | — | — | — | $0.00 |
Short side
FINRA· Oct 15, 2026SecBot reports
5 filings · 1 press release · 1 bullish · 1 bearish · 3 neutral- NEUTRAL 6-KSep 30, 2026
NuCana announced that the European Patent Office granted a composition-of-matter patent (EP…
Monitor for upcoming clinical data readouts from the NuTide:701 Phase 2 study of NUC-7738, which would be a more material catalyst than this patent grant. The cash runway into 2029 reduces near-term…
- NEUTRAL 6-KJun 8, 2026
NuCana plc held its Annual General Meeting on June 8, 2026, and all resolutions proposed in the…
Routine AGM filing with no new information. Monitor upcoming clinical or financial catalysts for NuCana, as this filing provides no trading signal.
- NEUTRAL 6-KJun 1, 2026
NuCana plc announced the appointment of Ian Webster as permanent Chief Financial Officer…
This CFO appointment is routine and unlikely to move the stock. Monitor upcoming Phase 2 data readouts for NUC-7738 in 2026 as the next catalyst. The cash runway into 2029 reduces near-term dilution…
- BULLISH 6-KMay 14, 2026
NuCana reported Q1 2026 results with a net loss of £3.9M, wider than the £2.5M loss in Q1 2025…
The FDA IND clearance for NUC-7738 is a significant de-risking catalyst that opens a U.S. regulatory pathway, and the cash runway into 2029 removes near-term dilution risk. Traders should watch for…
All NCNA filing & press-release reports (6)
- 6-K reportSep 30, 2026
- 6-K reportJun 8, 2026
- 6-K reportJun 1, 2026
- 6-K reportMay 14, 2026
- 6-K reportMay 6, 2026
- PRESS-RELEASE reportMar 19, 2026